Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome - Extension Study [EXTENSION OF 700210981]
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors SymBio Pharmaceuticals
- 14 Feb 2017 Status changed to completed.
- 08 Dec 2013 New trial record